Education
About Us
Working with TipRanks
Follow Us
Astrazeneca Plc (AZN)
NASDAQ:AZN
Total Valuation
AstraZeneca has a market cap or net worth of $212.97B. The enterprise value is ―.
Market Cap$212.97B
Enterprise Value―
Share Statistics
AstraZeneca has 3,101,276,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,101,276,900
Owned by Insiders―
Owned by Institutions5.89%
Financial Efficiency
AstraZeneca’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 10.30%.
Return on Equity (ROE)0.17
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)10.30%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee573.41K
Profits Per Employee92.16K
Employee Count94,300
Asset Turnover0.52
Inventory Turnover1.93
Valuation Ratios
The current PE Ratio of AstraZeneca is 57.74. AstraZeneca’s PEG ratio is -4.99.
PE Ratio57.74
PS Ratio0.00
PB Ratio10.94
Price to Fair Value9.96
Price to FCF49.16
Price to Operating Cash Flow34.32
PEG Ratio-4.99
Income Statement
In the last 12 months, AstraZeneca had revenue of 54.07B and earned 7.04B in profits. Earnings per share was 1.14.
Revenue54.07B
Gross Profit43.87B
Operating Income10.00B
Pretax Income8.69B
Net Income7.04B
EBITDA15.44B
Earnings Per Share (EPS)1.14
Cash Flow
In the last 12 months, operating cash flow was 13.09B and capital expenditures -3.95B, giving a free cash flow of 9.14B billion.
Operating Cash Flow13.09B
Free Cash Flow9.14B
Free Cash Flow per Share2.95
Dividends & Yields
AstraZeneca pays an annual dividend of $1.029, resulting in a dividend yield of 2.21%
Dividend Per Share$1.029
Dividend Yield2.21%
Payout Ratio35.16%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.39
52-Week Price Change-7.81%
50-Day Moving Average70.88
200-Day Moving Average72.31
Relative Strength Index (RSI)51.14
Average Volume (3m)6.44M
Important Dates
AstraZeneca upcoming earnings date is Jul 24, 2025, TBA Not Confirmed.
Last Earnings DateApr 29, 2025
Next Earnings DateJul 24, 2025
Ex-Dividend DateFeb 21, 2025
Financial Position
AstraZeneca as a current ratio of 0.93, with Debt / Equity ratio of 76.25%
Current Ratio0.93
Quick Ratio0.74
Debt to Market Cap0.07
Net Debt to EBITDA1.60
Interest Coverage Ratio5.95
Taxes
In the past 12 months, AstraZeneca has paid 1.65B in taxes.
Income Tax1.65B
Effective Tax Rate0.19
Enterprise Valuation
AstraZeneca EV to EBITDA ratio is 14.75, with an EV/FCF ratio of 31.30.
EV to Sales4.21
EV to EBITDA14.75
EV to Free Cash Flow31.30
EV to Operating Cash Flow19.20
Balance Sheet
AstraZeneca has $5.39B in cash and marketable securities with $31.29B in debt, giving a net cash position of $25.90B billion.
Cash & Marketable Securities$5.39B
Total Debt$31.29B
Net Cash$25.90B
Net Cash Per Share$8.35
Tangible Book Value Per Share-$5.59
Margins
Gross margin is 81.39%, with operating margin of 18.50%, and net profit margin of 13.01%.
Gross Margin81.39%
Operating Margin18.50%
Pretax Margin16.07%
Net Profit Margin13.01%
EBITDA Margin28.55%
EBIT Margin19.18%
Analyst Forecast
The average price target for AstraZeneca is $87.34, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$87.34
Price Target Upside25.33% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast15.48%
EPS Growth Forecast22.70%